PURPOSE: The mTOR kinase inhibitor AZD8055 inhibits both mTORC1 and mTORC2 leading to disruption of glucose metabolism and proliferation pathways. This study assessed the impact of single and multiple doses of AZD8055 on the uptake of the glucose metabolism marker 2-deoxy-2-[(18) F]fluoro-D-glucose ([(18) F]FDG) and the proliferation marker 3'-deoxy-3'-[(18) F]fluorothymidine ([(18) F]FLT) in U87-MG glioma xenografts. PROCEDURES: Mice bearing U87-MG tumours received either vehicle or AZD8055 (20 mg/kg) once daily p.o. Mice were imaged with either [(18) F]FDG or [(18) F]FLT PET to assess treatment response. Comparisons were made between in vivo imaging and ex vivo histopathology data. RESULTS: Tumour uptake of [(18) F]FDG was reduced by 33 % 1 h after a single dose of AZD8055 and by 49 % following 4 days of dosing. These changes coincided with suppression of the mTOR pathway biomarkers pS6 and pAKT. In contrast, the effect of AZD8055 on [(18) F]FLT uptake was inconsistent. CONCLUSIONS: The very rapid change in [(18) F]FDG uptake following acute AZD8055 treatment suggests that this could be used as an early mechanistic biomarker of metabolic changes resulting from mTOR inhibition. The utility of [(18) F]FLT for measuring the anti-proliferative effect of AZD8055 remains unclear.
PURPOSE: The mTOR kinase inhibitor AZD8055 inhibits both mTORC1 and mTORC2 leading to disruption of glucose metabolism and proliferation pathways. This study assessed the impact of single and multiple doses of AZD8055 on the uptake of the glucose metabolism marker 2-deoxy-2-[(18) F]fluoro-D-glucose ([(18) F]FDG) and the proliferation marker 3'-deoxy-3'-[(18) F]fluorothymidine ([(18) F]FLT) in U87-MG glioma xenografts. PROCEDURES: Mice bearing U87-MG tumours received either vehicle or AZD8055 (20 mg/kg) once daily p.o. Mice were imaged with either [(18) F]FDG or [(18) F]FLT PET to assess treatment response. Comparisons were made between in vivo imaging and ex vivo histopathology data. RESULTS: Tumour uptake of [(18) F]FDG was reduced by 33 % 1 h after a single dose of AZD8055 and by 49 % following 4 days of dosing. These changes coincided with suppression of the mTOR pathway biomarkers pS6 and pAKT. In contrast, the effect of AZD8055 on [(18) F]FLT uptake was inconsistent. CONCLUSIONS: The very rapid change in [(18) F]FDG uptake following acute AZD8055 treatment suggests that this could be used as an early mechanistic biomarker of metabolic changes resulting from mTOR inhibition. The utility of [(18) F]FLT for measuring the anti-proliferative effect of AZD8055 remains unclear.
Authors: George V Thomas; Chris Tran; Ingo K Mellinghoff; Derek S Welsbie; Emily Chan; Barbara Fueger; Johannes Czernin; Charles L Sawyers Journal: Nat Med Date: 2005-12-11 Impact factor: 53.440
Authors: Christine M Chresta; Barry R Davies; Ian Hickson; Tom Harding; Sabina Cosulich; Susan E Critchlow; John P Vincent; Rebecca Ellston; Darren Jones; Patrizia Sini; Dominic James; Zoe Howard; Phillippa Dudley; Gareth Hughes; Lisa Smith; Sharon Maguire; Marc Hummersone; Karine Malagu; Keith Menear; Richard Jenkins; Matt Jacobsen; Graeme C M Smith; Sylvie Guichard; Martin Pass Journal: Cancer Res Date: 2009-12-22 Impact factor: 12.701
Authors: Gayle Marshall; Zoe Howard; Jonathan Dry; Sarah Fenton; Dan Heathcote; Neil Gray; Heather Keen; Armelle Logie; Sarah Holt; Paul Smith; Sylvie M Guichard Journal: Biochem Soc Trans Date: 2011-04 Impact factor: 5.407
Authors: Nicolas Aide; Kathryn Kinross; Carleen Cullinane; Peter Roselt; Kelly Waldeck; Oliver Neels; Donna Dorow; Grant McArthur; Rodney J Hicks Journal: J Nucl Med Date: 2010-09-16 Impact factor: 10.057
Authors: Alexander R Guimaraes; Robert Ross; Jose L Figuereido; Peter Waterman; Ralph Weissleder Journal: Mol Imaging Biol Date: 2011-04 Impact factor: 3.488
Authors: Liu Hua Wei; Helen Su; Isabel J Hildebrandt; Michael E Phelps; Johannes Czernin; Wolfgang A Weber Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556